276 related articles for article (PubMed ID: 14973300)
1. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients.
Borgen LA; Okerholm RA; Lai A; Scharf MB
J Clin Pharmacol; 2004 Mar; 44(3):253-7. PubMed ID: 14973300
[TBL] [Abstract][Full Text] [Related]
2. Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.
Prescrire Int; 2007 Jun; 16(89):98-101. PubMed ID: 17582923
[TBL] [Abstract][Full Text] [Related]
3. Ultra-high-performance liquid chromatography tandem mass spectrometry determination of GHB, GHB-glucuronide in plasma and cerebrospinal fluid of narcoleptic patients under sodium oxybate treatment.
Tittarelli R; Pichini S; Pedersen DS; Pacifici R; Moresco M; Pizza F; Busardò FP; Plazzi G
Forensic Sci Int; 2017 May; 274():70-74. PubMed ID: 28139340
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.
Sleep; 2002 Feb; 25(1):42-9. PubMed ID: 11833860
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
Xyrem International Study Group
J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408
[TBL] [Abstract][Full Text] [Related]
6. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy.
Black J; Pardi D; Hornfeldt CS; Inhaber N
Sleep Med; 2009 Sep; 10(8):829-35. PubMed ID: 19616998
[TBL] [Abstract][Full Text] [Related]
7. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients.
Xyrem International Study Group
Sleep Med; 2005 Sep; 6(5):415-21. PubMed ID: 16099718
[TBL] [Abstract][Full Text] [Related]
8. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy.
Sleep; 2003 Feb; 26(1):31-5. PubMed ID: 12627729
[TBL] [Abstract][Full Text] [Related]
9. Sodium oxybate for cataplexy.
Lemon MD; Strain JD; Farver DK
Ann Pharmacother; 2006 Mar; 40(3):433-40; quiz 581-2. PubMed ID: 16507620
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers.
Thai D; Dyer JE; Jacob P; Haller CA
Clin Pharmacol Ther; 2007 Feb; 81(2):178-84. PubMed ID: 17192771
[TBL] [Abstract][Full Text] [Related]
11. [Integrated treatment of the symptoms of narcolepsy-cataplexy syndrome with sodium oxybate].
Poza-Aldea JJ
Rev Neurol; 2009 Jan 1-15; 48(1):27-31. PubMed ID: 19145563
[TBL] [Abstract][Full Text] [Related]
12. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
14. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy.
U.S. Xyrem Multicenter Study Group
Sleep Med; 2004 Mar; 5(2):119-23. PubMed ID: 15033130
[TBL] [Abstract][Full Text] [Related]
15. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.
Ondo WG; Perkins T; Swick T; Hull KL; Jimenez JE; Garris TS; Pardi D
Arch Neurol; 2008 Oct; 65(10):1337-40. PubMed ID: 18852348
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.
Wade M; Baker FJ; Roscigno R; DellaMaestra W; Arneson CP; Hunt TL; Lai AA
J Clin Pharmacol; 2004 May; 44(5):503-9. PubMed ID: 15102871
[TBL] [Abstract][Full Text] [Related]
17. Weight loss in narcolepsy patients treated with sodium oxybate.
Husain AM; Ristanovic RK; Bogan RK
Sleep Med; 2009 Jun; 10(6):661-3. PubMed ID: 19014899
[TBL] [Abstract][Full Text] [Related]
18. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
19. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate.
Huang YS; Guilleminault C
Pediatr Neurol; 2009 Jul; 41(1):9-16. PubMed ID: 19520267
[TBL] [Abstract][Full Text] [Related]
20. GHB levels in breast milk of women with narcolepsy with cataplexy treated with sodium oxybate.
Barker EC; Puchowicz M; Letterio J; Higgins K; Sharkey KM
Sleep Med; 2017 Aug; 36():172-177. PubMed ID: 28668666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
